CoChat
Sign Up
Cited by 111

Mechanistic model for production of recombinant adeno-associated virus via triple transfection of HEK293 cells

Nguyen, Tam N.T., Sha, Sha, Hong, Moo Sun, Maloney, Andrew J., Barone, Paul W., Neufeld, Caleb, Wolfrum, Jacqueline, Springs, Stacy L. +2 more·2021·Molecular Therapy - Methods & Clinical Development
DOI 10.1016/j.omtm.2021.04.006PMC PMC8143981
Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.omtm.2021.04.006

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Most existing viral vector models are vector specific and typically require re-derivation or extensive re-parameterization when applied to other viral systems.

    “Most existing models are vector specific and typically require re-derivation or extensive re-parameterization when applied to other viral systems.”

    From Mechanistic model for HEK293 viral vector processes and its application in a digital shadow framework (2026) · cites this paper as [17]

    In Materials and methods (Mathematical modeling; page unavailable), the paper says parameters from existing gene-delivery models did not fit its cell line or time course, so it re-estimated kinetic parameters. It does not say that most viral-vector models are vector specific or that applying them to other viral systems typically requires re-derivation or extensive re-parameterization. The Discussion (Conclusion; page unavailable) instead says its rAAV model can be adapted to other production methods and serotypes with small modifications. (LLM, conf=0.78)

    Experimental — accuracy not yet measured

  • For AAV, several mechanistic frameworks describe triple transfection dynamics, cell growth, metabolism, genome replication, and capsid formation.

    “For AAV, several mechanistic frameworks describe triple transfection dynamics, cell growth, metabolism, genome replication, and capsid formation [5, 16, 17].”

    From Mechanistic model for HEK293 viral vector processes and its application in a digital shadow framework (2026) · cites this paper as [17]

    The Introduction and Materials and methods describe a mechanistic model of triple transfection, viral DNA replication, and capsid formation. Materials and methods also includes a cell-growth parameter for dilution during cell division, but the paper does not model metabolism. The sentence cites three sources collectively, so this verdict concerns only what this paper supports. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

  • Several mechanistic modeling efforts have characterized HEK293 based viral vector production, although most of them remain vector specific.

    “Several mechanistic modeling efforts have characterized HEK293 based viral vector production, although most of them remain vector specific.”

    From Mechanistic model for HEK293 viral vector processes and its application in a digital shadow framework (2026) · cites this paper as [17]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 54

  1. [1]Wang D. Tai P.W.L. Gao G. Adeno-associated virus vector as a platform for gene therapy delivery Nat. Rev. Drug Discov. 18 2019 358 378 30710128 PMC6927556
  2. [2]Nonnenmacher M. Weber T. Intracellular transport of recombinant adeno-associated virus vectors Gene Ther. 19 2012 649 658 22357511 PMC4465241
  3. [5]Adamson-Small L. Potter M. Falk D.J. Cleaver B. Byrne B.J. Clément N. A scalable method for the production of high-titer and high-quality adeno-associated type 9 vectors using the HSV platform Mol. Ther. Methods Clin. Dev. 3 2016 16031 27222839 PMC4863725
  4. [6]Joshi P.R.H. Cervera L. Ahmed I. Kondratov O. Zolotukhin S. Schrag J. Chahal P.S. Kamen A.A. Achieving high-yield production of functional AAV5 gene delivery vectors via fedbatch in an insect cell-One Baculovirus system Mol. Ther. Methods Clin. Dev. 13 2019 279 289 30886878 PMC6404649
  5. [7]Wang Q. Dong B. Pokiniewski K.A. Firrman J. Wu Z. Chin M.P. Chen X. Liu L. Xu R. Diao Y. Xiao W. Syngeneic AAV pseudo-particles potentiate gene transduction of AAV vectors Mol. Ther. Methods Clin. Dev. 4 2016 149 158 28345000 PMC5363323
  6. [9]Wright J.F. Transient transfection methods for clinical adeno-associated viral vector production Hum. Gene Ther. 20 2009 698 706 19438300 PMC2829280
  7. [10]Chahal P.S. Schulze E. Tran R. Montes J. Kamen A.A. Production of adeno-associated virus (AAV) serotypes by transient transfection of HEK293 cell suspension cultures for gene delivery J. Virol. Methods 196 2014 163 173 24239634 PMC7113661
  8. [11]Zhao H. Lee K.-J. Daris M. Lin Y. Wolfe T. Sheng J. Plewa C. Wang S. Meisen W.H. Creation of a high-yield AAV vector production platform in suspension cells using a design-of-experiment approach Mol. Ther. Methods Clin. Dev. 18 2020 312 320 32671134 PMC7334306
  9. [12]Grieger J.C. Soltys S.M. Samulski R.J. Production of recombinant adeno-associated virus vectors using suspension HEK293 cells and continuous harvest of vector from the culture media for GMP FIX and FLT1 clinical vector Mol. Ther. 24 2016 287 297 26437810 PMC4817810
  10. [13]Blessing D. Vachey G. Pythoud C. Rey M. Padrun V. Wurm F.M. Schneider B.L. Déglon N. Scalable production of AAV vectors in orbitally shaken HEK293 cells Mol. Ther. Methods Clin. Dev. 13 2018 14 26 30591923 PMC6305802
  11. [14]Romitti P.A. Zhu Y. Puzhankara S. James K.A. Nabukera S.K. Zamba G.K.D. Ciafaloni E. Cunniff C. Druschel C.M. Mathews K.D. MD STARnet Prevalence of Duchenne and Becker muscular dystrophies in the United States Pediatrics 135 2015 513 521 25687144 PMC4477633
  12. [15]Flanigan K. Gene transfer clinical trial to deliver rAAVrh74.MCK.GALGT2 for Duchenne muscular dystrophy ClinicalTrials 2017 gov: NCT03333590 https://clinicaltrials.gov/ct2/show/NCT03333590 PMC9483573 36186954
  13. [17]Kyriakopoulos S. Ang K.S. Lakshmanan M. Huang Z. Yoon S. Gunawan R. Lee D.Y. Kinetic modeling of mammalian cell culture bioprocessing: the quest to advance biomanufacturing Biotechnol. J. 13 2018 e1700229 29027766
  14. [18]Varga C.M. Tedford N.C. Thomas M. Klibanov A.M. Griffith L.G. Lauffenburger D.A. Quantitative comparison of polyethylenimine formulations and adenoviral vectors in terms of intracellular gene delivery processes Gene Ther. 12 2005 1023 1032 15815703
  15. [19]Varga C.M. Hong K. Lauffenburger D.A. Quantitative analysis of synthetic gene delivery vector design properties Mol. Ther. 4 2001 438 446 11708880
  16. [20]Carpentier E. Paris S. Kamen A.A. Durocher Y. Limiting factors governing protein expression following polyethylenimine-mediated gene transfer in HEK293-EBNA1 cells J. Biotechnol. 128 2007 268 280 17118475
  17. [21]Glover D.J. Leyton D.L. Moseley G.W. Jans D.A. The efficiency of nuclear plasmid DNA delivery is a critical determinant of transgene expression at the single cell level J. Gene Med. 12 2010 77 85 19890943
  18. [23]Yates J. Warren N. Reisman D. Sugden B. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells Proc. Natl. Acad. Sci. USA 81 1984 3806 3810 6328526 PMC345309
  19. [24]Sun X. Goh P.E. Wong K.T.K. Mori T. Yap M.G.S. Enhancement of transient gene expression by fed-batch culture of HEK 293 EBNA1 cells in suspension Biotechnol. Lett. 28 2006 843 848 16786251
  20. [25]Zhou J. Yockman J.W. Kim S.W. Kern S.E. Intracellular kinetics of non-viral gene delivery using polyethylenimine carriers Pharm. Res. 24 2007 1079 1087 17387605
  21. [26]Lechardeur D. Sohn K.J. Haardt M. Joshi P.B. Monck M. Graham R.W. Beatty B. Squire J. O’Brodovich H. Lukacs G.L. Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer Gene Ther. 6 1999 482 497 10476208
  22. [27]Grosse S. Penaud-Budloo M. Herrmann A.-K. Börner K. Fakhiri J. Laketa V. Krämer C. Wiedtke E. Gunkel M. Ménard L. Relevance of assembly-activating protein for adeno-associated virus vector production and capsid protein stability in mammalian and insect cells J. Virol. 91 2017 e01198-17 28768875 PMC5625497
  23. [28]Redemann B.E. Mendelson E. Carter B.J. Adeno-associated virus rep protein synthesis during productive infection J. Virol. 63 1989 873 882 2536109 PMC247761
  24. [29]Dahari H. Ribeiro R.M. Rice C.M. Perelson A.S. Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells J. Virol. 81 2007 750 760 17035310 PMC1797446
  25. [30]Schwake G. Youssef S. Kuhr J.T. Gude S. David M.P. Mendoza E. Frey E. Rädler J.O. Predictive modeling of non-viral gene transfer Biotechnol. Bioeng. 105 2010 805 813 19953668
  26. [31]Myers M.W. Carter B.J. Assembly of adeno-associated virus Virology 102 1980 71 82 6245509
  27. [32]Young S.M. Jr. McCarty D.M. Degtyareva N. Samulski R.J. Roles of adeno-associated virus Rep protein and human chromosome 19 in site-specific recombination J. Virol. 74 2000 3953 3966 10756007 PMC111909
  28. [33]Tungtur S. Schwingen K.M. Riepe J.J. Weeramange C.J. Swint-Kruse L. Homolog comparisons further reconcile in vitro and in vivo correlations of protein activities by revealing over-looked physiological factors Protein Sci. 28 2019 1806 1818 31351028 PMC6739814
  29. [34]Cervera L. González-Domínguez I. Segura M.M. Gòdia F. Intracellular characterization of Gag VLP production by transient transfection of HEK 293 cells Biotechnol. Bioeng. 114 2017 2507 2517 28667757
  30. [35]Pollard H. Remy J.S. Loussouarn G. Demolombe S. Behr J.P. Escande D. Polyethylenimine but not cationic lipids promotes transgene delivery to the nucleus in mammalian cells J. Biol. Chem. 273 1998 7507 7511 9516451
  31. [36]Xie Q. Xinyong G. Xianjin C. Yayu W. PEI/DNA formation affects transient gene expression in suspension Chinese hamster ovary cells via a one-step transfection process Cytotechnology 65 2013 263 271 22782435 PMC3560876
  32. [37]Emmerling V.V. Pegel A. Milian E.G. Venereo-Sanchez A. Kunz M. Wegele J. Kamen A.A. Kochanek S. Hoerer M. Rational plasmid design and bioprocess optimization to enhance recombinant adeno-associated virus (AAV) productivity in mammalian cells Biotechnol. J. 11 2016 290 297 26284700
  33. [38]Hornstein B.D. Roman D. Arévalo-Soliz L.M. Engevik M.A. Zechiedrich L. Effects of circular DNA length on transfection efficiency by electroporation into HeLa cells PLoS ONE 11 2016 e0167537 27918590 PMC5137892
  34. [39]Pham P.L. Perret S. Cass B. Carpentier E. St-Laurent G. Bisson L. Kamen A. Durocher Y. Transient gene expression in HEK293 cells: peptone addition posttransfection improves recombinant protein synthesis Biotechnol. Bioeng. 90 2005 332 344 15803471
  35. [40]Grünberg J. Knogler K. Waibel R. Novak-Hofer I. High-yield production of recombinant antibody fragments in HEK-293 cells using sodium butyrate Biotechniques 34 2003 968 972 12765023
  36. [41]Hildinger M. Baldi L. Stettler M. Wurm F.M. High-titer, serum-free production of adeno-associated virus vectors by polyethyleneimine-mediated plasmid transfection in mammalian suspension cells Biotechnol. Lett. 29 2007 1713 1721 17636388
  37. [42]Gernaey K.V. Lantz A.E. Tufvesson P. Woodley J.M. Sin G. Application of mechanistic models to fermentation and biocatalysis for next-generation processes Trends Biotechnol. 28 2010 346 354 20416962
  38. [44]Fliedl L. Kast F. Grillari J. Wieser M. Grillari-Voglauer R. Optimization of a quantitative PCR based method for plasmid copy number determination in human cell lines N. Biotechnol. 32 2015 716 719 25796475
  39. [45]Guerin K. Rego M. Bourges D. Ersing I. Haery L. Harten DeMaio K. Sanders E. Tasissa M. Kostman M. Tillgren M. A novel next-generation sequencing and analysis platform to assess the identity of recombinant adeno-associated viral preparations from viral DNA extracts Hum. Gene Ther. 31 2020 664 678 32159396 PMC7310222
  40. [47]Maurer A.C. Weitzman M.D. Adeno-associated virus genome interactions important for vector production and transduction Hum. Gene Ther. 31 2020 499 511 32303138 PMC7232694
  41. [48]Matsushita T. Elliger S. Elliger C. Podsakoff G. Villarreal L. Kurtzman G.J. Iwaki Y. Colosi P. Adeno-associated virus vectors can be efficiently produced without helper virus Gene Ther. 5 1998 938 945 9813665
  42. [49]Shi Y. Seto E. Chang L.-S. Shenk T. Transcriptional repression by YY1, a human GLI-Krüppel-related protein, and relief of repression by adenovirus E1A protein Cell 67 1991 377 388 1655281
  43. [50]Chang L.S. Shi Y. Shenk T. Adeno-associated virus P5 promoter contains an adenovirus E1A-inducible element and a binding site for the major late transcription factor J. Virol. 63 1989 3479 3488 2545917 PMC250925
  44. [51]Graham F.L. Smiley J. Russell W.C. Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5 J. Gen. Virol. 36 1977 59 74 886304
  45. [52]Louis N. Evelegh C. Graham F.L. Cloning and sequencing of the cellular-viral junctions from the human adenovirus type 5 transformed 293 cell line Virology 233 1997 423 429 9217065
  46. [53]Huang M.M. Hearing P. Adenovirus early region 4 encodes two gene products with redundant effects in lytic infection J. Virol. 63 1989 2605 2615 2724411 PMC250738
  47. [54]Li J. Samulski R.J. Xiao X. Role for highly regulated rep gene expression in adeno-associated virus vector production J. Virol. 71 1997 5236 5243 9188591 PMC191759
  48. [55]Pereira D.J. McCarty D.M. Muzyczka N. The adeno-associated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection J. Virol. 71 1997 1079 1088 8995628 PMC191159
  49. [56]Trempe J.P. Carter B.J. Regulation of adeno-associated virus gene expression in 293 cells: control of mRNA abundance and translation J. Virol. 62 1988 68 74 2824856 PMC250502
  50. [57]Dubielzig R. King J.A. Weger S. Kern A. Kleinschmidt J.A. Adeno-associated virus type 2 protein interactions: formation of pre-encapsidation complexes J. Virol. 73 1999 8989 8998 10516005 PMC112931
  51. [59]King J.A. Dubielzig R. Grimm D. Kleinschmidt J.A. DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids EMBO J. 20 2001 3282 3291 11406604 PMC150213
  52. [62]Dietmair S. Hodson M.P. Quek L.-E. Timmins N.E. Gray P. Nielsen L.K. A multi-omics analysis of recombinant protein production in Hek293 cells PLoS ONE 7 2012 e43394 22937046 PMC3427347
  53. [63]Hong M.S. Velez-Suberbie M.L. Maloney A.J. Biedermann A. Love K.R. Love J.C. Mukhopadhyay T.K. Braatz R.D. Macroscopic modeling of bioreactors for recombinant protein producing Pichia pastoris in defined medium Biotechnol. Bioeng. 118 2021 1199 1212 33274756
  54. [65]Weinstein M.J. Rao A.V. Algorithm 984: ADiGator, a toolbox for the algorithmic differentiation of mathematical functions in MATLAB using source transformation via operator overloading ACM Trans. Math. Softw. 44 2017 21

Cited by

Sorted by citations

Authors
Nguyen, T. N. T., Sha, S., Hong, M. S., Maloney, A. J., Barone, P. W., Neufeld, C., Wolfrum, J., Springs, S. L., Sinskey, A. J., & Braatz, R. D.
ORCID
Venue
Molecular Therapy - Methods & Clinical Development
Publisher
Elsevier BV
Published
2021-06
Volume
21
Pages
642-655
ISSN
2329-0501
DOI
10.1016/j.omtm.2021.04.006
PMC
PMC8143981
Cited by
111
References
2
Language
en
Licence
Funders
  • National Science Foundation Directorate for Education and Human Resources (1122374)
  • Mathworks Inc
  • National Science Foundation
  • U.S. Food and Drug Administration (1R01FD006584-02)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review